**Name: Pasquale Innominato**

**Qualifications**

M.D.; Ph.D.

**Job title**

Consultant in Medical Oncology

Visiting Professor, Wrexham Glyndwr University

Honorary Associate Clinical Professor, Warwick University

**Profile**

I am employed by Betsi Cadwaladr University Health Board (BCUHB) as a Consultant in Medical Oncology, and my current research work is centred on cancer.

​

I hold honorary positions in the Schools of Biomedical Sciences affiliated with Wrexham Glyndwr and Warwick universities.

I obtained my Degree in Medicine and my specialisation in Medical Oncology in Italy, and my Doctorate in Sciences (Medicine and Pharmacology) in France, where I have worked before moving to the UK.

My research goal is to improve cancer care through harnessing digital tools (mHealth apps; wearable biosensors) and through accounting for our biological rhythms around 24 hours. These so-called circadian rhythms include rest-activity and sleep-wake cycles, hormones, physical and mental performance as well as molecular pathways of each cell.

Certain cancer patients display disrupted circadian rhythms, as a consequence of their disease and/or anticancer treatment, and this alteration negatively impacts on their outcome and well-being. Digital tools and advanced analytics allow the phenotyping of circadian function and open to novel therapeutic interventions. Thus, my goal is to improve both the efficacy and the tolerance of anticancer drugs, as well as the wellbeing and experience with care of cancer patients.

I am keen to supervise trainees increase their research potential and to open to new multidisciplinary collaborations, spanning experimental, translational and clinical research.

In the limited time outside of work, I enjoy spending time with my family and friends, exploring Wales, cooking and photographing. I am keen but poor in team ball sports and old-fashioned board games.

**Current Research interests:**

Specifically, my current research interests are the followings:

***Circadian rhythms***

• Chronomedicine

• Chronopharmacology

• Chronotherapy

 ***Digital health***

• mHealth in Oncology

• Remote phenotyping

• Advanced multidimensional analytics

***Integrative oncology***

• Behavioural medicine

• Health-related quality of life

• Supportive cancer care

• Biomarker discovery

• Drug repurposing

**Latest publications (2020-date)**

Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer.

Dulong S, Huang Q, Innominato PF, Karaboue A, Bouchahda M, Pruvost A, Théodoro F, Agrofoglio LA, Adam R, Finkenstädt B, Lévi F.

Sci Rep. 2021 Dec 14;11(1):24015. doi: 10.1038/s41598-021-03247-2.

Evaluation and Management of Sleep and Circadian Rhythm Disturbance in Cancer.

Balachandran DD, Miller MA, Faiz SA, Yennurajalingam S, Innominato PF.

Curr Treat Options Oncol. 2021 Jul 2;22(9):81. doi: 10.1007/s11864-021-00872-x.

Timing of blood sampling to alleviate chemotherapy contraindications.

Vangara JL, Innominato PF, Levi FA.

Support Care Cancer. 2022 Jan;30(1):3-4. doi: 10.1007/s00520-021-06256-z.

Impact of assessment frequency of patient-reported outcomes: an observational study using an eHealth platform in cancer patients.

Innominato PF, Komarzynski S, Dallmann R, Wreglesworth NI, Bouchahda M, Karaboué A, Ulusakarya A, Subbe CP, Spiegel D, Lévi FA.

Support Care Cancer. 2021 Nov;29(11):6167-6170. doi: 10.1007/s00520-021-06262-1.

Embracing Change: Learnings From Implementing Multidimensional Digital Remote Monitoring in Oncology Patients at a District General Hospital During the COVID-19 Pandemic.

Komarzynski S, Wreglesworth NI, Griffiths D, Pecchia L, Subbe CP, Hughes SF, Davies EH, Innominato PF.

JCO Clin Cancer Inform. 2021 Feb;5:216-220. doi: 10.1200/CCI.20.00136.

The challenge of offering potentially curative treatment to patients with esophageal cancer and a history of liver transplantation: A literature review and case report.

Halle-Smith JM, Hall LA, Innominato PF, Wadhwani S, Perera MTPR, Griffiths EA.

Surgery. 2021 Jun;169(6):1379-1385. doi: 10.1016/j.surg.2020.12.015.

Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.

Innominato PF, Karaboué A, Focan C, Chollet P, Giacchetti S, Bouchahda M, Ulusakarya A, Torsello A, Adam R, Lévi FA, Garufi C.

Int J Cancer. 2020 Dec 3;148(10):2512-21. doi: 10.1002/ijc.33422.

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer.

Bouchahda M, Saffroy R, Karaboué A, Hamelin J, Innominato P, Saliba F, Lévi F, Bosselut N, Lemoine A.

JCO Precis Oncol. 2020 Sep 16;4:PO.19.00400. doi: 10.1200/PO.19.00400. eCollection 2020.

Checklists for Complications During Systemic Cancer Treatment Shared by Patients, Friends, and Health Care Professionals: Prospective Interventional Cohort Study.

Jones HV, Smith H, Cooksley T, Jones P, Woolley T, Gwyn Murdoch D, Thomas D, Foster B, Wakefield V, Innominato P, Mullard A, Ghosal N, Subbe C.

JMIR Mhealth Uhealth. 2020 Sep 25;8(9):e19225. doi: 10.2196/19225.

Tele-Monitoring of Cancer Patients' Rhythms during Daily Life Identifies Actionable Determinants of Circadian and Sleep Disruption.

Lévi F, Komarzynski S, Huang Q, Young T, Ang Y, Fuller C, Bolborea M, Brettschneider J, Fursse J, Finkenstädt B, White DP, Innominato P.

Cancers (Basel). 2020 Jul 17;12(7):1938. doi: 10.3390/cancers12071938.

A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.

Ulusakarya A, Karaboué A, Ciacio O, Pittau G, Haydar M, Biondani P, Gumus Y, Chebib A, Almohamad W, Innominato PF.

BMC Cancer. 2020 Jun 3;20(1):515. doi: 10.1186/s12885-020-07004-y.

Hepatic metastases resection after cetuximab: are we missing something?

Ulusakarya A, Innominato PF, Bouchahda M, Levi FA, Adam R.

Lancet Oncol. 2020 May;21(5):e228. doi: 10.1016/S1470-2045(20)30144-3.

Does circadian rhythm influence gastrointestinal toxicity?

Hofmeister EN, Fisher S, Palesh O, Innominato PF.

Curr Opin Support Palliat Care. 2020 Jun;14(2):120-126. doi: 10.1097/SPC.0000000000000498.

Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.

Innominato PF, Ballesta A, Huang Q, Focan C, Chollet P, Karaboué A, Giacchetti S, Bouchahda M, Adam R, Garufi C, Lévi FA.

Cancer Med. 2020 Jun;9(12):4148-4159. doi: 10.1002/cam4.3056.

A novel approach to management of sleep-associated problems in patients with breast cancer (MOSAIC) during chemotherapy : A pilot study.

Palesh O, Solomon N, Hofmeister E, Jo B, Shen H, Cassidy-Eagle E, Innominato PF, Mustian K, Kesler S.

Sleep. 2020 Oct 13;43(10):zsaa070. doi: 10.1093/sleep/zsaa070.

Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy.

Hill RJW, Innominato PF, Lévi F, Ballesta A.

PLoS Comput Biol. 2020 Jan 27;16(1):e1007218. doi: 10.1371/journal.pcbi.1007218. eCollection 2020 Jan.

***Open Researcher & Contributor ID (ORCID):***

0000-0002-0653-8261